Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (12514)	2/25/1999 11:48:00 AM
From: Bidder	Respond to of 25711

Joe, What's going on With JTAN?

To: Joe Copia who wrote (12514)	2/25/1999 12:38:00 PM
From: Blitz	Respond to of 25711

KANA News! (BSNS WIRE) Kanakaris Announces $5 Million Line of Credit to Pursue Inte Kanakaris Announces $5 Million Line of Credit to Pursue Internet Opportunities Business Editors and High-Tech Writers NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb. 25, 1999-- Alliance Equities Inc. Provides Kanakaris With Support for its Internet LifeStyle eCommerce Development Kanakaris Communications Inc. (OTC BB:KANA) Thursday announced the receipt of a $5 million line of credit from Alliance Equities Inc., a Florida-based venture capital firm, to pursue current Internet opportunities, eCommerce development, and a possible stock buy back program. Richard Epstein, president of Alliance Equities, stated: "We are very excited to be involved with Kanakaris. We are providing Kanakaris with the funding needed to explore various current Internet opportunities, including the start-up of the Internet LifeStyle Network which will be a groundbreaking eCommerce Web site including auctions of specialty items. Kanakaris will also explore a possible stock buy back program." Alex Kanakaris, chief executive officer of Kanakaris Communications, stated that the relationship with Alliance "Will jump start the company's efforts with our Internet LifeStyle Network Web site, and allow us to explore the possibility of a stock buy back program, as well as other expansion and opportunities on behalf of our shareholders." A Memorandum of Understanding was signed with a definitive agreement scheduled to follow within seven days. The line of credit is immediately available to Kanakaris, according to Alliance Equities. Kanakaris Communications is traded on the OTC Bulletin Board and the Frankfurt Stock Exchange. For further information on Kanakaris Communications (www.kanakaris.com) contact Colby Marceau, director of public/investor relations at 714/444-0560; fax 714/549-8970; e-mail info@kanakaris.com; 3303 Harbor Blvd., No. F-3, Costa Mesa, Calif., 92626. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussions, the words "plan," "confident that," "believe," "expect," "intend to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties, and actual results could differ materially from those expressed in any forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings, and other risks. --30--JS/np* RMS/np CONTACT: Kanakaris Communications, Costa Mesa Colby Marceau, 714/444-0560 info@kanakaris.com KEYWORD: CALIFORNIA INDUSTRY KEYWORD: COMED INTERACTIVE/MULTIMEDIA/INTERNET COMPUTERS/ELECTRONICS Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *

To: Joe Copia who wrote (12514)	2/25/1999 12:40:00 PM
From: Quasar	Read Replies (1) \| Respond to of 25711

ADVR starting to move on news: February 25, 1999 11:39 Antiviral from Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor for HIV YONKERS, N.Y.--(BW HealthWire)--Feb. 25, 1999--Advanced Viral Research Corp. (OTC BB:ADVR) announced Thursday that its scientists have discovered that its lead antiviral drug, Reticulose, inhibited the production of a key cellular receptor for HIV. Using CD4 positive T-lymphocytes, the scientists found that Reticulose markedly decreased the number of cellular CCR5 receptors. The CCR5 receptor is one of the three most important cell receptors needed by the AIDS virus, HIV, to attach to its target cells and initiate infection. Interference with the function of the CCR5 cellular chemokine receptor is known to increase the resistance of T-lymphocytes and macrophages to HIV infection. A mutation in the CCR5 gene, especially prevalent in individuals of northern European descent, appears to render these individuals resistant to infection by HIV. Commenting on this research, Dr. Shalom Z. Hirschman, president and CEO of Advanced Viral Research Corp., stated: "The exciting discovery by our scientists that the immunomodulator, Reticulose, interferes with the production of the CCR5 receptor, offers a novel approach to the development of therapeutic agents for HIV infection. This new finding may account, in part, for the beneficial effects of Reticulose in the treatment of HIV infected individuals observed in preliminary clinical trials. Furthermore, this new pathway of inhibiting HIV infection suggests that combination therapy with Reticulose may enhance the therapeutic effectiveness of the AIDS cocktails currently in use." Reticulose is a peptide nucleic acid preparation produced by Advanced Viral Research Corp., which, based on previous history, has been shown to be effective against a number of viral diseases. For further information, contact Mark Amster at 954/458-7636. NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. RETICULOSE is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. CONTACT: Advanced Viral Research Corp., Hallandale, Fla. Mark Amster, 954/458-7636